CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of initial clinical data from the FORTRESS study of NG-350A, an oncolytic immunotherapy for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. The ongoing
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
